Member Info for EmeraldCarrots

As an option for catching the circulating tumour cells (CTC'S) soon. The deal means Qiagen can subcontract the catching of the CTC's to Cellbxhealth Plc. The CTC's have a shelf life of about 4 days. With some of Qiagens existing tests the shelf life is just 4 hours which must be a massive problem. Should not be long now.

https://www.qiagen.com/us/product-categories/diagnostics-and-clinical-research

Correction. A lot of item 3 below.

Doc3.

What valuation do you think EC?

AN always talked in billions.

A billion would almost be 100p, so 100x SP.

Is that realistic?

===============================

It all depends on some big unanswered questions.

1. What do Immatics need from the analysis of the circulating tumour cells? Are they just for, all be it very important, helping to select the most suitable candidates for the personalised cancer drug treatment? Or is there more to it than that. Do they need to do the analysis also to get vital cancer cell information (proteins, DNA, RNA etc.) that enables them to "reprogram" the T cells? Are they unable to do this without live intact cancer cells to analyse? If this is the case, and the current phase 3 trial is a success, then is it not a blank cheque?

2. As Immatics are having a lot of success using Parsortix with Immunotherapy cancer drugs are other Companies going to use Parsortix more? Seems to make a lot of sense. Is there about to be a plethora of good news from Cellbxhealth Plc? I would not be surprised at all. In fact I am once again astonished at the markets muted reaction.

3. Dual analysis. It is proven that dual analysis finds about twice the number of ***CANCER BIOMARKERS*** Ctdna does alone. This in itself to me at least is totally astonishing. Yet the reaction from the industry is muted. Dual analysis is DNA testing the CTC's caught from a blood sample using Parsortix and then performing the same "standard" CtDna analysis on the same blood sample. Catching live, intact, uncontaminated CTC's using the Parsortix machine enables this DNA analysis to be done. Most other methods of catching CTC's damage the cells and/or contaminate them making DNA analysis difficult or pointless. Even Illumina have effectively confirmed this and in fact helped Angle plc, now Cellbxhealth Plc produce an assay tp perform dual analysis on lung cancer patients and find about twice the number of cancer biomarkers. What more does the market want? I think the market is asleep to all this. I find it amazing, and in fact incredibly sad.

Doc 3.

If the share price shot up to 10p a share in days from here I honestly would not be surprised. I am heavily invested and am glad I am.

All IMHO.

Doc3.

What valuation do you think EC?

AN always talked in billions.

A billion would almost be 100p, so 100x SP.

Is that realistic?

===============================

It all depends on some big unanswered questions.

1. What do Immatics need from the analysis of the circulating tumour cells? Are they just for, all be it very important, helping to select the most suitable candidates for the personalised cancer drug treatment? Or is there more to it than that. Do they need to do the analysis also to get vital cancer cell information (proteins, DNA, RNA etc.) that enables them to "reprogram" the T cells? Are they unable to do this without live intact cancer cells to analyse? If this is the case, and the current phase 3 trial is a success, then is it not a blank cheque?

2. As Immatics are having a lot of success using Parsortix with Immunotherapy cancer drugs are other Companies going to use Parsortix more? Seems to make a lot of sense. Is there about to be a plethora of good news from Cellbxhealth Plc? I would not be surprised at all. In fact I am once again astonished at the markets muted reaction.

3. Dual analysis. It is proven that dual analysis finds about twice the number of CTC's Ctdna does alone. This in itself to me at least is totally astonishing. Yet the reaction from the industry is muted. Logic tells me that if a blood test like Parsortix actually physically finds, and catches real, live, intact, uncontaminated circulating tumour cells it is undeniable they exist! It's asif the industry thinks it is not true! Even Illumina have effectively confirmed this and in fact helped Angle plc, now Cellbxhealth Plc produce an assay tp perform dual analysis on lung cancer patients. What more does the market want? I think the market is asleep to all this. I find it amazing, and in fact incredibly sad.

Doc 3.

If the share price shot up to 10p a share in days from here I honestly would not be surprised. I am heavily invested and am glad I am.

All IMHO.

Fuselage panel defect only might affect deliveries, not planes in service so all seems well.

Doc3.

What valuation do you think EC?

AN always talked in billions.

A billion would almost be 100p, so 100x SP.

Is that realistic?

===============================

It all depends on some big unanswered questions.

1. What do Immatics need from the analysis of the circulating tumour cells? Are they just for, all be it very important, helping to select the most suitable candidates for the personalised cancer drug treatment? Or is there more to it than that. Do they need to do the analysis also to get vital cancer cell information (proteins, DNA, RNA etc.) that enables them to "reprogram" the T cells? Are they unable to do this without live intact cancer cells to analyse? If this is the case, and the current phase 3 trial is a success, then is it not a blank cheque?

2. As Immatics are having a lot of success using Parsortix with Immunotherapy cancer drugs are other Companies going to use Parsortix more? Seems to make a lot of sense. Is there about to be a plethora of good news from Cellbxhealth Plc? I would not be surprised at all. In fact I am once again astonished at the markets muted reaction.

3. Dual analysis. It is proven that dual analysis finds about twice the number of CTC's Ctdna does alone. This in itself to me at least is totally astonishing. Yet the reaction from the industry is muted. Logic tells me that if a blood test like Parsortix actually physically finds, and catches real, live, intact, uncontaminated circulating tumour cells it is undeniable they exist! It's asif the industry thinks it is not true! Even Illumina have effectively confirmed this and in fact helped Angle plc, now Cellbxhealth Plc produce an assay tp perform dual analysis on lung cancer patients. What more does the market want? I think the market is asleep to all this. I find it amazing, and in fact incredibly sad.

Doc 3.

If the share price shot up to 10p a share in days from here I honestly would not be surprised. I am heavily invested and am glad I am.

All IMHO.

Https://clinicaltrials.gov/study/NCT06946225?spons=immatics&rank=3

https://clinicaltrials.gov/study/NCT03686124?term=anzu-cel&rank=2

https://clinicaltrials.gov/study/NCT06743126?term=anzu-cel&rank=3

https://clinicaltrials.gov/study/NCT06967961?term=parsortix&rank=8

https://clinicaltrials.gov/study/NCT05648240?term=parsortix&rank=9

https://clinicaltrials.gov/study/NCT06904625?term=parsortix&rank=4

================

I make it 1356 participants in these trials x how many times a blood sample is needed per person. Could easily be half a dozen over many months. 6 x 1356 = 8136. However there are many more trials going on that use Parsortix. We only know about the Immatics 3 trials because Cellbxhealth told us. A search for "Parsortix" would NOT have found those 3 trials. It may well be that Parsortix is vital to Immatics in that they may well need the data from the live, intact, uncontaminated CTC's the Parsortix machine can deliver. Quite possible IMHO.

https://immatics.com/our-pipeline/

All IMHO.

Https://clinicaltrials.gov/study/NCT06946225?spons=immatics&rank=3

https://clinicaltrials.gov/study/NCT03686124?term=anzu-cel&rank=2

https://clinicaltrials.gov/study/NCT06743126?term=anzu-cel&rank=3

https://clinicaltrials.gov/study/NCT06967961?term=parsortix&rank=8

https://clinicaltrials.gov/study/NCT05648240?term=parsortix&rank=9

https://clinicaltrials.gov/study/NCT06904625?term=parsortix&rank=4

A.I.

==============

Immatics uses the Parsortix system as a core component of its "liquid biopsy" approach to capture and analyze viable circulating tumor cells (CTCs) from patient blood samples. This non-invasive method allows Immatics to:

Identify and validate cancer targets for their specialized immunotherapy drugs, such as those in their ACTengine® platform.

Profile the molecular makeup (DNA, RNA, and protein analysis) of cancer cells to better understand the genetic and molecular characteristics of a patient's specific cancer.

Stratify patients in clinical trials to ensure the right patients are selected for targeted treatments.

Monitor treatment effectiveness and track how a tumor changes over time, including the development of resistance mechanisms.

The ability of the Parsortix system to harvest live, intact, and uncontaminated CTCs is crucial for the detailed downstream molecular analysis needed for Immatics' precision medicine and T-cell receptor (TCR) therapy development programs. The technology is being used in at least three of Immatics' cancer drug trials, including a Phase 3 study for advanced melanoma (the SUPRAME trial for the therapy known as anzu-cel or IMA203).

==============

Parsortix is massively undervalued IMHO. It is ridiculous in the extreme.

https://immatics.com/our-pipeline/

All IMHO.

Up to 4 days after capture. This is because the circulation tumor cells are 99% live and intact when caught. Other methods of caoture damage the CTC's so they have to be processed about twice as quickly. Obviously this means CTC's caught using parsortix can be posted to and from Cellbxhealth's lab in Guildford, in the UK. No wonder Myriad Genetics plc are looking at possibly using Parsortix. Also Qiagen is promoting it alongside other methods. The far longer time frame is crucial.

All IMHO.

Because they are live and intact last about twice as long in a standard blood test tube before needing to be processed.

=============

A.I.

The difference in required processing times for Qiagen's AdnaTest (4 hours) and Parsortix (8 hours with standard EDTA tubes) is due to their distinct mechanisms of action and the specific preservation of target cells and their components (mRNA vs. physical cell integrity).

AdnaTest (4 hours)

Mechanism and Target: The AdnaTest is designed for the detection of specific mRNA biomarkers (e.g., KLK3, PSMA, EGFR) in captured circulating tumor cells (CTCs).

Time Sensitivity: RNA is a highly unstable molecule with a very short half-life and is prone to rapid degradation by circulating RNases and cell lysis outside the body. This degradation starts immediately after the blood is drawn.

Requirement: To ensure the integrity and reliable detection of these specific mRNA transcripts, the sample must be processed quickly (within 4 hours) and typically transported on ice to minimize RNA degradation. Delayed processing can lead to false-negative results or altered gene expression profiles, making the data unreliable for analysis.

Parsortix (8 hours)

Mechanism and Target: The Parsortix system is a size- and deformability-based microfluidic technology that enriches intact CTCs from whole blood. Its primary goal is the physical capture of the cells themselves, which can then be used for various downstream analyses, including cell culture, DNA analysis, or immunofluorescent staining.

Time Sensitivity: While all blood samples degrade over time, the Parsortix method is more robust to the initial post-collection changes compared to the AdnaTest's delicate mRNA target. Studies show that using standard K2EDTA tubes, the cell capture rate remains stable for longer, with processing recommended within 8 hours for optimal results.

Flexibility with Preservatives: The Parsortix system also has the advantage of being compatible with specialized preservative-containing blood collection tubes (e.g., CellSave or Transfix tubes). When these tubes are used, the processing window can be extended significantly, up to 96 hours (4 days) at room temperature, because the fixatives help maintain cell membrane integrity and prevent degradation.

In essence, the AdnaTest's shorter window is due to the extreme fragility of its target analyte (mRNA), while the Parsortix system's reliance on physical cell capture allows for a slightly more forgiving processing timeframe with standard tubes and even longer stability with specialized preservative tubes.

===========================================

VERY interesting indeed!

So other methods of catching CTC's have yet another problem. They can't be stored anywhere near as long because the CTC's get damaged and contaminated when caught so they degrade about twice as quick. When compatible specialized preservative-containing blood collection tubes with Parsortix it is up to 4 days. This is extremely

A.I.

using Parsortix? Integrating the Parsortix system would allow Myriad Genetics' Precise Tumor analysis to

transition from a tissue-only test to a blood-based liquid biopsy test, making the analysis less invasive, potentially faster, and more accessible for patients.

Key Improvements

Minimally Invasive Procedure: The primary improvement is the ability to use a simple blood draw (liquid biopsy) instead of relying solely on conventional solid tumor tissue biopsies, which are often invasive, painful, and may not be feasible for all patients.

Improved Patient Access and Monitoring: By utilizing circulating tumor cells (CTCs) harvested from blood, clinicians can obtain actionable genomic information more easily. This allows for:

Repeat testing: Monitoring a patient's response to treatment over time with serial blood tests, which is difficult with repeated tissue biopsies.

Broader application: Providing genomic insights to patients who cannot undergo a tissue biopsy due to the tumor's location or their medical condition.

Enhanced Downstream Analysis: The Parsortix system captures intact, viable CTCs, which allows for comprehensive downstream molecular analysis, including DNA and RNA sequencing, protein analysis, and whole-cell imaging. This provides robust material for Myriad's existing, comprehensive assays which use both DNA and RNA sequencing to detect more variants.

Potential for Real-time Information: A blood test can potentially provide faster results than traditional tissue biopsy logistics, leading to quicker, more informed treatment decisions.

Complementary Data: Myriad could combine its existing expertise in tissue-based assays with the liquid biopsy data from Parsortix-harvested CTCs, providing a more complete picture of the tumor biology and its evolution.

The current collaboration is a research project designed to validate that the DNA from Parsortix-harvested CTCs can produce comparable results to Myriad's established tissue assays, with the ultimate goal of integrating this liquid biopsy approach into routine clinical use.

Yet Parsortix ones in 8 or more?

A.I.

The difference in required processing times for AdnaTest (4 hours) and Parsortix (8 hours with standard EDTA tubes) is

due to their distinct mechanisms of action and the specific preservation of target cells and their components (mRNA vs. physical cell integrity).

AdnaTest (4 hours)

Mechanism and Target: The AdnaTest is designed for the detection of specific mRNA biomarkers (e.g., KLK3, PSMA, EGFR) in captured circulating tumor cells (CTCs).

Time Sensitivity: RNA is a highly unstable molecule with a very short half-life and is prone to rapid degradation by circulating RNases and cell lysis outside the body. This degradation starts immediately after the blood is drawn.

Requirement: To ensure the integrity and reliable detection of these specific mRNA transcripts, the sample must be processed quickly (within 4 hours) and typically transported on ice to minimize RNA degradation. Delayed processing can lead to false-negative results or altered gene expression profiles, making the data unreliable for analysis.

Parsortix (8 hours)

Mechanism and Target: The Parsortix system is a size- and deformability-based microfluidic technology that enriches intact CTCs from whole blood. Its primary goal is the physical capture of the cells themselves, which can then be used for various downstream analyses, including cell culture, DNA analysis, or immunofluorescent staining.

Time Sensitivity: While all blood samples degrade over time, the Parsortix method is more robust to the initial post-collection changes compared to the AdnaTest's delicate mRNA target. Studies show that using standard K2EDTA tubes, the cell capture rate remains stable for longer, with processing recommended within 8 hours for optimal results.

Flexibility with Preservatives: The Parsortix system also has the advantage of being compatible with specialized preservative-containing blood collection tubes (e.g., CellSave or Transfix tubes). When these tubes are used, the processing window can be extended significantly, up to 96 hours (4 days) at room temperature, because the fixatives help maintain cell membrane integrity and prevent degradation.

In essence, the AdnaTest's shorter window is due to the extreme fragility of its target analyte (mRNA), while the Parsortix system's reliance on physical cell capture allows for a slightly more forgiving processing timeframe with standard tubes and even longer stability with specialized preservative tubes.

===========================================

VERY interesting indeed!

96 hours (4 days) after collection if cellsave tubes used for the blood sample.

All IMHO.

For optimal results, blood samples for the Parsortix system should be processed within 8 hours of collection when using K2EDTA tubes.

Studies have shown the following timeframes for sample processing with the Parsortix system, depending on the blood collection tube used:

K2EDTA Tubes: Processing within 8 hours is the standard protocol used in multiple clinical studies.

CellSave Tubes: Samples collected in CellSave preservative tubes have been successfully processed up to 96 hours (4 days) after collection.

Transfix Tubes: Use of Transfix blood collection tubes has shown stable cell capture rates when processed at 0 hours, 24 hours, or even up to 72 hours after collection.

The ability to use cryopreservation also allows samples to be stored for extended periods and analyzed by Parsortix later, providing flexibility for specific research applications. The appropriate timeframe depends on the specific protocol and the type of downstream analysis planned, as the user is responsible for validating their specific downstream assay.

Pros of the AdnaTest

Molecular Characterization: The test allows for sensitive analysis of cancer-associated gene expression profiles in enriched tumor cells via reverse transcription (RT) and multiplex PCR. This provides insights into tumor biology, relevant biomarkers (e.g., AR-V7 in prostate cancer, HER2 in breast cancer), and mechanisms of therapy resistance like epithelial-mesenchymal transition (EMT).

High Specificity and Sensitivity: It uses a "Combination of Combinations Principle" (COCP), which involves an optimized combination of antibodies for immunomagnetic cell selection and specific mRNA markers for detection, leading to high analytical specificity and sensitivity.

Reduced Leukocyte Bias: The AdnaWash Leukocyte Reducer buffer helps minimize contamination from white blood cells (WBCs), which is critical for accurate analysis of rare CTCs.

Open Platform: The system is an open platform, allowing researchers flexibility to add or profile their own custom-selected mRNA targets for comprehensive biomarker discovery.

Minimally Invasive: As a liquid biopsy test, it only requires a blood draw, which is less invasive and less risky than traditional tissue biopsies.

Workflow Efficiency: The test provides results relatively quickly, with the whole process from sample to result taking around 5-8 hours.

Cons of the AdnaTest

Inability to Exactly Quantify CTCs: PCR-based methods like the AdnaTest cannot exactly quantify the number of CTCs present in a sample, as quantifying transcript levels does not differentiate between a high number of cells with low expression and a low number of cells with high expression.

Loss of Cells During Processing: The isolation process involving magnetic beads can result in the loss of cells during transfer steps, affecting overall recovery and making it unsuitable for precise enumeration.

Cannot Differentiate Cell Viability: RT-PCR-based techniques hamper differentiation between viable and non-viable cells, which might be important for prognostic information.

Marker Dependence: The immunomagnetic selection relies on specific epithelial markers (like EpCAM). CTCs that undergo EMT may lose these markers and thus be missed, leading to potential false-negative results.

Sample Handling Requirements: Blood samples need to be processed rapidly (within 4 hours of the draw) to maintain sample integrity and ensure optimal results, creating logistical challenges compared to methods with longer sample stability.

Lower Sensitivity in Some Cases: In some studies, other microfluidic devices were found to detect much higher levels of cancer-associated gene expression and more reliably isolate CTCs than the AdnaTest.

=================================================

This is why they are looking at Parsortix.

Their existing circulating tumor cell(CTC) analysis menu to include live, intact, uncontaminated CTC's (caught using Parsortix) which offer the chance for more in depth CTC analysis:-

https://www.qiagen.com/us/applications/liquid-biopsy/ctc

What analyzing CTCs can tell you:

Cancer prognosis: The number of CTCs can be correlated with a patient's prognosis, with higher counts often indicating a worse outlook.

Treatment effectiveness: Repeated testing can show whether a cancer is responding to treatment by monitoring if the CTC count is increasing or decreasing.

Metastasis potential: The characteristics of CTCs can help predict the cancer's potential to spread, as these are the cells that have already entered the bloodstream.

Tumor heterogeneity: By analyzing multiple CTCs, researchers can map the genetic abnormalities and understand the diversity of the tumor, which is **crucial for personalized medicine**. - Immatics.............

Treatment guidance: CTCs can be used to test how a patient's cancer might respond to different therapies in a lab setting, which can help identify effective drug targets.

Tumor evolution: CTC analysis can reveal how the cancer is evolving and developing resistance to treatment over time, which can be a crucial factor in guiding future therapy.

Diagnosis and monitoring: They can be used for early cancer detection and long-term monitoring of the disease through a less invasive "liquid biopsy" compared to traditional tissue biopsies.

============================

Parsortix is being used in 3 Immatics cancer drug trials. One is at phase 2 and one at phase 3.

Anzu-cel(IMA203). See here:-

https://immatics.com/our-pipeline/

Medical use using the already in use dual analysis assay for lung cancer? This is currently available from Cellbxhealth Plc as a service, but does not have FDA clearance to be used with actual medical diagnosis. Can be used in cancer drug trials which could lead to that. Fact is it obviously does "what it says in the tin" but it costs serious cash to get FDA approval. This Company has so much going for it. With the right finanacing or partner to help provide the finance. We have just raised £8.5 million and are now collaborating with Myriad Genetics, Qiagen and of course Illumina. The future is looking very good here.

All IMHO.

Is asleep. In the land of nod. Potential exclusive agreements:-

A.I.

CellBxHealth could potentially enter into various types of exclusive agreements related to its Parsortix platform and services, provided these agreements comply with competition law and serve the company's strategic goals.

Potential exclusive agreements could include:

Exclusive Distribution Agreements: Granting a single partner exclusive rights to sell the Parsortix platform and its consumables within a specific geographic region or to a defined customer group (e.g., all hospital labs in a particular country).

Exclusive Licensing Agreements: Licensing its proprietary Parsortix technology exclusively to a larger diagnostic or pharmaceutical company for the development and commercialization of a specific companion diagnostic assay or a particular LDT (Laboratory Developed Test). The recent agreement with QIAGEN mentions an "opportunity for the development of a companion diagnostic assay," which could potentially become an exclusive arrangement later.

Exclusive R&D Collaborations: Partnering with a single pharmaceutical company for R&D efforts on a specific drug target or in a particular cancer type, where CelLBxHealth would be the sole provider of CTC analysis for that program.

Exclusive Laboratory Service Contracts: Securing an exclusive contract to provide all CTC-based clinical trial support and assay development services for a large biopharma partner's entire oncology pipeline.

Acquisition-related Exclusivity: As part of a potential M&A scenario (either CelLBxHealth as the acquirer or the target), the parties would typically enter into an exclusivity agreement to prevent the target from negotiating with other potential buyers for a specified period.

Conifer Management, LLC, on behalf of the Acacia funds ("Acacia''), has subscribed for a further 40,891,541 New Ordinary Shares at the Issue Price ("Additional Subscription Shares") by way of a direct subscription ("Additional Subscription"), raising further gross proceeds of approximately £0.4 million. Acacia was the largest participant in the Fundraising and the Additional Subscription allows Acacia to ensure that it will hold 29.9% of the issued share capital following Second Admission. The Fundraising (including the Additional Subscription) has raised, in aggregate, gross proceeds of approximately £8.2 million.

https://www.lse.co.uk/rns/CLBX/additional-subscription-rxw5wrp5piz078c.html